University of Iowa Research Foundation

University of Michigan

Michael K Schultz

Somya Kapoor

Mengshi Li

Douglas R Spitz, Jr

Dongyoul Lee

Christopher Pigge

Nicholas Baumhover

Frances L Johnson

Molly Martin

Max S Wicha

Bryan G Allen

Moustafa Tarek Ahmed Ibrahim Gabr

Fenghuang Zhan

Andrean L Simons-Burnett

Mahboubeh Varmazyad

Prabhat C Goswami

Kyle Kloepping

Yueming Zhu

Nukhet Aykin-Burns

F Christoper Pigge

Garry R Buettner

Edwin Sagastume

Moustafa Gabr

Joseph Cullen

F Christopher Pigge

Joshua Schoenfeld

Jessica Reedy

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I wherein T is a SST2R targeting ligand, L is a linker, and X is a chelator, for the therapeutic treatment of cancer, and methods of use thereof.

Structural optimization method to improve the theranostic performance of peptide receptor-targeted radionuclide therapy for cancers

The present invention provides in certain embodiments a carcinoma-targeting conjugate comprising Formula I:T-L-X

A method of performing a chelating reaction comprising contacting a divalent metal with a compound of Formula (I): or a salt thereof wherein: each of R-Ris independently selected from the group consisting of CHCOORand CHC(═O)NHR; each of R-Ris independently selected from the group consisting of H and -L-X; each Ra is independently selected from the group consisting of H and -L-X; each L is independently selected from the group consisting of absent and a linking group; and each X is a biological agent; and wherein the contacting occurs at a temperature below about 40° C. to form a chelated composition.

Compositions for chelating metals at low temperatures

The invention provides compositions and methods to treat a hyperproliferative disorder with a GSH synthesis inhibitor and an anti-cancer composition.

Compositions and methods for treating cancer

The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula I:T-L-Xwherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula I.

Compositions and methods of treating melanoma

The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, comprising administering an MCR1 ligand to a patient in need thereof. The present invention also provides in certain embodiments a melanoma-targeting conjugate comprising Formula (I): T-L-X wherein T is a MCR1 ligand, L is a linker, and X an anti-cancer composition, for the therapeutic treatment of a hyperproliferative disorder. The present invention also provides methods, kits and uses of the conjugate of Formula (I).

The invention provides compositions and methods to treat a hyperproliferative disorder with phenyl butyric acid (PBA) or a pharmaceutically acceptable salt thereof and an anti-cancer composition.

The invention provides compositions and methods to treat a hyperproliferative disorder with ascorbate or a pharmaceutically acceptable salt thereof, at least one chelating agent that enhances ascorbate redox cycling (EDTA) to form HO, and one or more anti-cancer therapies.

Compositions and methods for cancer therapy

The invention provides a method to treat cancer in an animal comprising administering a tetra-arylethylene cation to the animal.

Image guided therapy for cancer

The invention provides compositions and methods to treat cancer with an agent that increases reactive oxygen species (ROS) levels in cancer cell mitochondria ('an XTPP agent') or a pharmaceutically acceptable salt thereof, an inhibitor of hydroperoxide metabolism and a pharmaceutically acceptable diluent or carrier.

Growing community of inventors

Iowa City, IA, United States of America

Michael K Schultz